ASTRO 2023

Questions discussed in this category

What is your preferred PMRT dose/fractionation for patients with implant reconstruction?

Did your treatment inclinations change with the results of the recent FABREC trial (NCT03422003) presented at ASTRO?

1 Answer available

What are your top takeaways from ASTRO 2023?

What were your “Top 3” Presentations/Studies from the meeting this year? How will it impact your clinical practice?

5 Answers available

Papers discussed in this category

Lancet Oncol,

Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.

NPJ precision oncology, 2023 Oct 02

Pre-radiotherapy ctDNA liquid biopsy for risk stratification of oligometastatic non-small cell lung cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 Aug 22

De Novo Oligometastatic Breast Cancer.

Related Topics